PHASE 2 STUDY OF ALDOXORUBICIN VERSUS TOPETECAN FOR RELAPSED/REFRACTORY SMALL CELL LUNG CANCER

被引：0
|
作者：
Wieland, S. [1 ]
Mita, A. [2 ]
Piantadosi, S. [2 ]
Natale, R. [2 ]
Levitt, D. [3 ]
机构：
[1] CytRx Corp, Clin Operat, Los Angeles, CA USA
[2] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA
[3] CytRx Corp, Clin Dev, Los Angeles, CA USA
来源：
ANNALS OF ONCOLOGY | 2014年 / 25卷
关键词：
D O I：
10.1093/annonc/mdu355.16
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1478TiP
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Topotecan every 28 days in refractory or relapsed small cell lung cancer
    Safont, M
    Berrocal, A
    Martinez, N
    Camps, C
    Blasco, A
    Garde, J
    Gavila, Q
    Juarez, A
    Iranzo, V
    Sirera, R
    LUNG CANCER, 2005, 49 : S327 - S327
  • [42] Single agent immunotherapy for relapsed or refractory small cell lung cancer (rrSCLC).
    Singh, Ankur
    Ahmed, Tamjeed
    Dothard, Andy
    Grant, Stefan C.
    Ruiz, Jimmy
    Farris, Michael
    Petty, William J.
    Lycan, Thomas
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Irinotecan in combination with platinum in refractory or relapsed small cell lung cancer.
    Yu, Shufei
    Wang, Yan
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [44] Phase II study of NK012 in relapsed small cell lung cancer
    Raefsky, E.
    Spigel, D. R.
    Infante, J. R.
    Bendell, J. C.
    Jones, S. F.
    Lipman, A. J.
    Trent, D.
    Kawamura, S.
    Greco, F. A.
    Hainsworth, J. D.
    Burris, H. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [45] A phase II study of S-1 in relapsed small cell lung cancer
    Kudo, Keita
    Ohyanagi, Fumiyosi
    Horiike, Atsushi
    Miyauchi, Eisaku
    Tahanaka, Hisashi
    Yanagitani, Noriko
    Saito, Ryouta
    Kaburaki, Kyouhei
    Sakatani, Toshio
    Horai, Takeshi
    Nishio, Makoto
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (02) : 263 - 266
  • [46] Phase 2 Study of Talazoparib Plus Low-Dose Temozolomide in Patients with Relapsed/Refractory Extensive-Stage Small Cell Lung Cancer
    Cummings, A.
    Goldman, J.
    Mendenhall, M.
    Kanamori, D.
    Nguyen, A.
    Kim, D.
    Wainberg, Z.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S815 - S816
  • [47] Phase II Trial of metronomic Temozolomide and Topotecan in patients with relapsed and/or refractory Small Cell Lung Cancer.
    Bhattacharyya, Gouri Shankar
    Parikh, Purvish M.
    Biswas, Ghanashyam
    Bondarde, Shailesh A.
    Malhotra, Hemant
    Vora, Amish
    Govindbabu, K.
    Ranade, Anantbhushan A. B.
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S743 - S743
  • [48] Phase II trial of amrubicin and carboplatin in patients with sensitive or refractory relapsed small-cell lung cancer
    Hirose, Takashi
    Nakashima, Masanao
    Shirai, Takao
    Kusumoto, Sojiro
    Sugiyama, Tomohide
    Yamaoka, Toshimitsu
    Okuda, Kentaro
    Ohnishi, Tsukasa
    Ohmori, Tohru
    Adachi, Mitsuru
    LUNG CANCER, 2011, 73 (03) : 345 - 350
  • [49] Phase III study of aldoxorubicin vs investigators' choice as treatment for relapsed/refractory soft tissue sarcomas
    Chawla, Sant P.
    Ganjoo, Kristen N.
    Schuetze, Scott
    Papai, Zsuzsanna
    Van Tine, Brian Andrew
    Choy, Edwin
    Liebner, David A.
    Agulnik, Mark
    Chawla, Shanta
    Wieland, Scott
    Levitt, Daniel J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] A Phase Ib/II Study of Ganetespib With Doxorubicin in Advanced Solid Tumors Including Relapsed-Refractory Small Cell Lung Cancer
    Subramaniam, Deepa S.
    Liu, Stephen V.
    Crawford, Jeanette
    Kramer, Jenna
    Thompson, Jillian
    Wang, Hongkun
    Giaccone, Giuseppe
    FRONTIERS IN ONCOLOGY, 2018, 8
12345